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Abstract
Background: The transcription factors CCAAT/enhancer binding proteins (C/EBP) a, b and δ have been shown to
be expressed in brain and to be involved in regulation of inflammatory genes in concert with nuclear factor B
(NF-B). In general, C/EBPa is down-regulated, whereas both C/EBPb and δ are up-regulated in response to
inflammatory stimuli. In Alzheimer’s disease (AD) one of the hallmarks is chronic neuroinflammation mediated by
astrocytes and microglial cells, most likely induced by the formation of amyloid-b (Ab) deposits. The inflammatory
response in AD has been ascribed both beneficial and detrimental roles. It is therefore important to delineate the
inflammatory mediators and signaling pathways affected by Ab deposits with the aim of defining new therapeutic
targets.
Methods: Here we have investigated the effects of Ab on expression of C/EBP family members with a focus on
C/EBPδ in rat primary astro-microglial cultures and in a transgenic mouse model with high levels of fibrillar Ab
deposits (tg-ArcSwe) by western blot analysis. Effects on DNA binding activity were analyzed by electrophoretic
mobility shift assay. Cross-talk between C/EBPδ and NF-B was investigated by analyzing binding to a B site using
a biotin streptavidin-agarose pull-down assay.
Results: We show that exposure to fibril-enriched, but not oligomer-enriched, preparations of Ab inhibit up-
regulation of C/EBPδ expression in interleukin-1b-activated glial cultures. Furthermore, we observed that, in aged
transgenic mice, C/EBPa was significantly down-regulated and C/EBPb was significantly up-regulated. C/EBPδ,o n
the other hand, was selectively down-regulated in the forebrain, a part of the brain showing high levels of fibrillar
Ab deposits. In contrast, no difference in expression levels of C/EBPδ between wild type and transgenic mice was
detected in the relatively spared hindbrain. Finally, we show that interleukin-1b-induced C/EBPδ DNA binding
activity to both C/EBP and B sites is abolished after exposure to Ab.
Conclusions: These data suggest that both expression and function of C/EBPδ are dysregulated in Alzheimer’s
disease. C/EBPδ seems to be differently regulated in response to different conformations of Ab. We propose that
Ab induces an imbalance between NF-B and C/EBP transcription factors that may result in abnormal responses to
inflammatory stimuli.
Background
Alzheimer’s disease (AD) is a neurodegenerative disor-
der and is the most common cause of dementia among
the elderly. Accumulation of amyloid-b (Ab) peptides in
the brain is considered to be a key step in the pathogen-
esis of the disease and leads to formation of amyloid
plaques in brain parenchyma. The Ab peptides can be
truncated at both the C- and N-terminal ends, and also
undergo posttranslational modifications. Although Ab1-
40 (40 amino acids long) is the most abundant form,
t h em a j o rf o c u si so nA b1-42 which is more prone to
aggregate and considered to be the most neurotoxic
form. Ab i sf o u n di nd i f f e r e n ta g g r e g a t i o ns t a t e si nt h e
brain ranging from monomers and non-fibrillar aggre-
gates, termed oligomers, to a highly fibrillar form found
in the deposits. Recent evidence suggests that diffusible
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e v e r ,i ts h o u l da l s ob en o t e dt h a tA b fibril-containing
senile plaques precede the development of dystrophic
neurites [3] and of spinodendritic calcium decompart-
mentalization that presumably leads to cognitive dys-
function [4]. In addition to massive neurodegeneration,
chronic neuroinflammation is a pathological hallmark of
AD, manifested by activated microglia and reactive
astrocytes. Accumulation and deposition of Ab can trig-
ger activation of glial cells, which will set off an inflam-
matory response that, over time, becomes chronic
causing a persistent deleterious condition [5].
The role of neuroinflammation in the development
and progression of AD is, however, not clear. Neuroin-
flammation is often referred to as a “double-edged
sword”. On the one hand microglia and astrocytes
secrete inflammatory cytokines, chemokines and neuro-
toxins upon activation, and can thereby promote neuro-
nal degeneration. On the other hand, activated microglia
surrounding Ab plaques may have beneficial effects by
phagocytosis of, and thus elimination of, Ab [6]. Astro-
cytes have also been reported to be able to migrate
towards Ab plaques and, upon contact, to degrade Ab
[7,8]. This somewhat confusing picture calls for delinea-
tion of signaling pathways that may be involved in the
beneficial effects of neuroinflammation or that may pro-
mote neurodegeneration.
The inflammatory response is, to a large degree, orche-
strated by the transcription factor nuclear factor B( N F -
B). However, NF-B works in concert with other tran-
scription factors. Of particular interest are members of
the CCAAT/enhancer binding protein (C/EBP) family
that can amplify the effects of NF-Ba n dm a ya l s of o r m
heteromeric complexes with NF-B [9-11]. C/EBP is a
protein family consisting of six members, C/EBPa-ζ
(reviewed in [12]). In order to be active, C/EBPs will
form homo- or heterodimers with each other or with
other transcription factors. Until recently, C/EBP studies
have mainly focused on the liver, where these proteins
regulate expression of a variety of genes including acute
phase proteins [13]. However, C/EBPa, b and δ are also
all expressed in brain [14,15]. Among their target genes
are many pro-inflammatory cytokines including interleu-
kin- (IL-) 6 (an early inflammatory marker in AD brain),
inducible nitric oxide synthase, complement factors, and
cyclooxygenase-2 (COX-2) [16]. In both brain and liver,
inflammatory stimuli have been shown to, in general,
down-regulate expression of C/EBPa and up-regulate
expression of C/EBPb and δ [15]. Several previous studies
have suggested that members of the C/EBP transcription
factor family are dysregulated in AD and in response to
Ab. mRNA levels of C/EBPa, b and δ have all been
shown to be up-regulated in hippocampus of AD patients
[17-19] and protein levels of C/EBPδ have also been
reported to be up-regulated in AD brain [20]. However,
in a recent study we observed that C/EBPδ DNA binding
activity to a C/EBP motif is, instead, completely blocked
in IL-1b-stimulated primary astro-microglial cultures
from rats after exposure to oligomeric forms of Ab pep-
tides [21]. It can be speculated that Ab peptides cause an
imbalance between NF-B and C/EBP transcription fac-
tors that could result in abnormal responses to inflam-
matory stimuli. To further investigate how the
inflammatory response in the AD brain may be affected
we have analyzed the effects of different aggregation
states of Ab on NF-B-C/EBP cross-talk, and also C/
EBPa and δ expression levels in activated primary glial
cultures. In addition, we have analyzed the expression
levels of C/EBPa, b and δ and in mice with high levels of
fibrillar Ab deposits.
Methods
Primary astro-microglial cultures and treatments
Primary mixed glial cultures consisting of 5-10% micro-
glia and 90-95% astrocytes (hereafter referred to as
astro-microglial cultures) were obtained from male
Sprague Dawley pups less than 24 h of age as previously
described [22]. The experimental procedures were
approved by Stockholm North Local Committee on
Ethics of Animal Experiments and performed in accor-
dance with international standards on animal welfare.
Cells were seeded in 60 mm culture dishes and main-
tained in DMEM glutamax containing 10% fetal bovine
serum (FBS) and 0.1% penicillin-streptomycin (PEST)
for 20-22 days (all from GIBCO). Medium was
exchanged every 3-4 day. 18 h prior to experiment,
medium was exchanged to DMEM glutamax containing
0.2% FBS and 0.1% PEST. Confluent cells were exposed
to 10 μMA b(1-42), 10 μMA b(42-1) (American pep-
tide), 10 ng/ml rat recombinant IL-1b (Biosource) and/
or 1 μg/ml lipopolysaccharide (LPS, Sigma) for 3 h
before analysis. Ab preparations enriched in oligomeric
or fibrillar forms were prepared as previously described
[23,24]. Briefly, Ab was dissolved in hexafluoroisopropa-
nol (HFIP) to a final concentration of 1 mM. HFIP was
then removed by centrifugation under vacuum, and Ab
was then resuspended in dimethyl sulfoxide (DMSO,
Sigma) to a final concentration of 5 mM. To obtain oli-
gomers, culture medium was added to the peptide to a
final concentration of 100 μM followed by an incubation
at 4°C for 24 h. For a fibril-enriched preparation,
10 mM HCl was added to the peptide to a final concen-
tration of 100 μM, followed by incubation for 24 h at
37°C. The different Ab preparations were analyzed using
western blot (see western blot) and Thioflavin T assay
(T3516, Sigma). In the Thioflavin T assay, Ab samples
were analyzed in phenol red-free medium and according
to the manufacturer’s instructions.
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Nuclear extracts were prepared as follows: cells were
washed in ice-cold PBS, scraped and subsequently cen-
trifuged for 2 min. Thereafter the pellet was washed
again in PBS, centrifuged for 25 s and resuspended in
HB buffer (10 mM Tris HCl pH 7.4, 10 mM KCl, 1.5
mM MgCl2, 0.5 mM PMSF, 0.5 mM b-mercaptoetha-
nol), centrifuged for 25 s and resuspended in lysis buffer
(HB buffer, 0.4% Nonidet-40). Samples were then lysed
on ice for 10 min. Nuclear fractions were pelleted by
centrifugation for 5 min, and then resuspended in buffer
C (10 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1
mM DTT, 1 mM PMSF) and thereafter placed on a
shaking platform for 30 min and centrifuged for 5 min.
The supernatant containing nuclear extract was col-
lected and stored at -80°C for approximately 24 h before
use. All steps were performed at 4°C and all centrifuga-
tions were performed at 16,000 g.
Transgenic mice
Transgenic mice, tg-ArcSwe, carrying both the Artic
(E693G) and the Swedish (KM670/671NL) APP double
mutations were originally of C57Bl/6-CBA-F1 background
[25], but then bred on a C57Bl/6 background for more
than six generations (incipient congenics). The experi-
ments were approved by an ethical committee (Uppsala
djurförsöksetiska nämnd) and performed in compliance
with national and local animal care and use guidelines
(protocol #C223/8). Animals were 15.5-17 month of age
when sacrificed. At this age tg-ArcSwe mice have pre-
viously been shown to possess a plaque burden of approxi-
mately 4%, as measured by Ab immunostaining of tissue
sections followed by quantitative image analysis [26,27].
Mice were anesthetized with 0.3 ml Avertin (25 mg/ml)
and intracardially perfused with 0.9% saline solution. The
brains were removed and dissected into amyloid-contain-
ing forebrain (including cortex and hippocampus) and
amyloid-sparse hindbrain (cerebellum and brainstem) (cf.
[25]). After dissection the samples were snap-frozen and
stored in liquid nitrogen until use. As a control for changes
related to age and Ab deposition in the animals, 4 month-
old tg-ArcSwe and non-transgenic animals were also inves-
tigated. Protein lysates were prepared as follows: forebrain
and hindbrain were homogenized in ice-cold RIPA buffer
(50 mM Tris HCl pH 8, 150 mM NaCl, 1% Nonidet-40,
0.5% sodium deoxycholate, 1% SDS, 1 mM PMSF) to a
concentration of 25 mg/ml and placed on a shaking plat-
form for 5 h at 4°C. Thereafter the samples were centri-
fuged for 20 min at 9,500 g and the protein containing
supernatant was collected and stored at -80°C until used.
Ab ELISA
For measurement of total Ab levels, ninety-six-well
plates were coated with 50 ng/well of the N-terminal
Ab-specific antibody 82E1 (IBL-Hamburg, Hamburg,
Germany) in PBS and blocked with 1% BSA in PBS with
0.15% Kathon (Rohm & Haas, Philadelphia, PA). Brain
tissues homogenized in RIPA-buffer were supplemented
with formic acid (to a final concentration of 70%), neu-
tralized with 1 M Tris (pH 10) and diluted in ELISA
incubation buffer (PBS with 0.1% BSA and 0.05%
Tween-20). Samples or standard (recombinant Arctic
Ab1-40), were treated similarly, and added to the plates
in duplicates and incubated for 2 h at room temperature
with shaking. Biotinylated mAb27 (1 μg/ml), with a con-
formation-dependent epitope in the mid-domain of Arc-
tic Ab [28], was used to measure total Ab.T h e
biotinylated detection antibody as well as streptavidin-
horseradish peroxidase (SA-HRP; diluted 1:2000; Mab-
tech, Nacka, Sweden) was allowed to incubate for 1 h in
successive steps. K-blue aqueous (ANL-Produkter,
Älvsjö, Sweden) was used as HRP-substrate, the reaction
was stopped with 1 M H2SO4 and the optical density
was measured at 450 nm with a SpectraMax 190 (Mole-
cular Devices, Sunnyvale, CA). Wells were washed three
times between each step in ELISA washing buffer (PBS
with 0.1% Tween-20 and 0.15% Kathon).
Western blot
Protein concentrations were estimated using Bicinchoni-
nic acid assay (BCA, Pierce). Protein lysates (20 μg/lane
from primary astro-microglial cultures and 40 μg/lane
from transgenic mice tissues) were mixed with Laemmli
sample buffer and boiled for 5 min. Proteins were sepa-
rated on 12% SDS-polyacrylamide gels and thereafter
blotted onto polyvinylidene diflouride (PVDF) mem-
branes (Amersham Pharmacia). For analysis of oligomer-
and fibril-enriched Ab preparations, samples were not
preheated and they were run on a 12% SDS-polyacryla-
mide gel without stacking gel. The membranes were
incubated in PBS containing 5% milk, 0.1% Tween-20
(Bio-Rad) and 0.1% BSA (Sigma) for 2 h at room tem-
perature to block unspecific binding, and thereafter
incubated in the above-mentioned PBS solution with
primary antibody overnight at 4°C. Antibody concentra-
t i o n sw e r ea sf o l l o w s :C / E B P a ((14AA)X) and C/EBPδ
((C-22)X, Santa Cruz Biotechnologies) 1:4000 for pri-
mary astro-microglial cultures and 1:1000 for transgenic
samples, b-actin (A-2066, Sigma) 1:5000 and 6E10
(ab49682, Abcam) raised against Ab(1-17) 1:2000. Next,
membranes were washed in PBS containing 2.5% milk
and 0.1% Tween-20 for 4 × 15 min and thereafter incu-
bated with secondary antibody HRP coupled anti-rabbit
IgG or anti-mouse IgG (GE Healthcare) 1:5000, diluted
i nt h es a m es o l u t i o n ,f o r1ha tr o o mt e m p e r a t u r e .
Finally, membranes were washed 4 × 15 min in PBS
containing 0.1% Tween-20. Blots were incubated in ECL
Plus reagents (GE Healthcare) for 5 min and exposed to
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anti-C/EBPb ((C19)X, Santa Cruz Biotechnologies) were
f i r s tw a s h e d5m i ni nT B Sa n dr i n s e d1 0si nm e t h a n o l
[29]. Thereafter the membranes were allowed to dry
before overnight incubation at 4°C with primary anti-
body, 1:500, diluted in TBS containing 5% milk and
0.05% Tween-20. Membranes were then washed 2 × 15
s in TBS containing 0.05% Tween-20 and incubated for
1 h at RT with secondary antibody (HRP coupled anti-
rabbit IgG) 1:5000, diluted in TBS containing 5% milk
and 0.05% Tween-20. Finally, membranes were washed
2 × 30 min in TBS containing 0.05% Tween-20, incu-
bated in ECL Plus reagents for 5 min and exposed to
Hyper film.
Electrophoretic mobility shift assay (EMSA)
Protein concentrations were established using BCA
assay. EMSA was performed as previously described
[21,30] with minor modifications. Briefly, C/EBP sense
oligonucleotide 5’-TGCAGATTGCGCAATCTGCA-3
(MWG) was labeled with g-
32Pd A T P( P e r k i nE l m e r )
using T4 polynucleotide kinase (Fermentas). Nuclear
extracts (5 μg) from primary astro-microglial cultures
were incubated with anti-C/EBPδ ((C-22) X, Santa Cruz
Biotechnologies) for 30 min at room temperature prior
to binding reaction with
32P-labeled probe. Samples
were separated on a 5% polyacrylamide gel at 150 V for
1 h. Gels were exposed to a phosphorimager screen
overnight.
Streptavidin-agarose pull-down assay
C/EBPδ binding to the B DNA element was analyzed
by streptavidin-agarose pull-down [31,32]. Single
stranded biotinylated B sense oligonucleotide 5’-
AGTTGAGGGGACTTTCCCAGGC-3’ and antisense
oligonucleotide 5’-GCCTGGGAAAGTCCCCTCAACT-
3’ (MWG), were hybridized by incubation at 100°C for 1
h and then allowed to cool down slowly (for approx. 30
min) to room temperature. Nuclear extracts (150 μg)
from primary astro-microglial cultures were mixed with
streptavidin-agarose bead suspension (according to the
manufacturer’s recommendation; S1638, Sigma) and 4
μg of double stranded biotinylated oligonucleotides in
500 μlo fb u f f e rB 2( P B S ,1m ME D T A ,1m MD T T ,
protease inhibitor cocktail Complete (Roche Diagnos-
tics)). The mixture was then placed on a shaking plat-
form for 2 h at room temperature. Thereafter the
samples were centrifuged at 550 g for 1 min and the
pellet washed 3 times in buffer B2. Finally the pellet was
dissolved in 35 μl 2x Laemmli sample buffer, incubated
at 100°C for 5 min and centrifuged at 7000 g for 30 s
and the supernatant was collected. Samples were loaded
on a 12% SDS-polyacrylamide gel and analyzed by wes-
tern blot. As a control for unspecific binding to the
agarose beads, identical B oligonucleotides lacking bio-
tin were used.
Statistical analysis
Data was analyzed using student’s t-test or one-way
ANOVA followed by Tukey’s post hoc test.
Results
Fibril-enriched Ab preparations down-regulate levels of C/
EBPδ in activated primary astro-microglial cells
The effect of Ab on expression levels of C/EBPa and δ
in primary astro-microglial cells was analyzed by wes-
tern blot. Two different preparations of Ab1-42 were
used: one containing high levels of oligomers and one
containing high levels of fibrils. The different Ab pre-
parations were analyzed using western blot and Thiofla-
v i nTa s s a y( F i g u r e1 A , B ) .C e l l sw e r et r e a t e dw i t hA b
enriched in oligomers or fibrils in the presence or
absence of IL-1b (10 ng/ml) for 3 h prior to harvesting
and preparing nuclear extracts. IL-1b,w h i c hi sk n o w n
to be induced in AD brains, was used to activate the
cells. For comparison, cells were also treated with LPS
(1 μg/ml). Two different isoforms of C/EBPa;p 3 0a n d
p42, which were both significantly down-regulated by
LPS treatment, were detected (Figure 1C,D and 2A,B).
This is consistent with earlier findings in primary glial
cultures showing that C/EBPa is mainly regulated
through toll-like receptors [33]. Neither Ab nor IL-1b
alone had any effect on the levels of the two isoforms of
C/EBPa. However, it should be noted that the levels of
p30 and p42 appeared to be reduced when cell cultures
were stimulated with fibril-enriched Ab preparations
together with IL-1b although this effect was not statisti-
cally significant.
Both IL-1b and LPS induced up-regulation of C/
EBPδ (Figure 1C,E and 2A,C). Ab enriched in oligo-
mers (Figure 1C,E) or fibrils (Figure 2A,C) did not
have any significant effect on basal C/EBPδ levels.
However, treatment with Ab containing high levels of
fibrils did significantly decrease IL-1b-induced C/EBPδ
levels by ~75% (Figure 2A,C). Neither Ab preparations
devoid of fibrils nor the reversed peptide Ab42-1
(prepared as the Ab1-42), used as a control, had any
effect on IL-1b-stimulated up-regulation of C/EBPδ
(Figure 1C,E and 2A,C).
C/EBPδ levels are decreased in brain areas of tg-ArcSwe
mice rich in amyloid plaques
Based on these results, the effects of Ab fibrils in vivo
were investigated. Tg-ArcSwe mice (15.5-17-months-
old), with both the Artic (E693G) and Swedish (KM670/
671NL) APP double mutations, were chosen since aged
animals exhibit an abundance of Ab fibrils [26]. A sig-
nificant down-regulation of C/EBPa was found in both
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Page 4 of 13Figure 1 Oligomer-enriched Ab has no effect on IL-1b-induced C/EBPδ expression levels in rat primary astro-microglial cultures.A )
Representative western blot of Ab preparations used for cell treatments showing the presence of high levels of fibrillar Ab only in the fibril-
enriched preparation (lane 2) and not in the oligomeric-enriched preparation (lane 1). B) Statistical analysis of Thioflavin T fluorescence in the
presence of fibril-enriched Ab preparation (fAb; open bar) and oligomer-enriched Ab preparation (oAb; filled bar). The data represent mean ±
SEM for four independent experiments. A.U., arbitrary units. C) Representative western blot of C/EBPa (p42 and p30) and C/EBPδ in primary
astro-microglial cultures from rat. Cells were exposed to an Ab preparation mainly consisting of oligomers for 3 h. 20 μg of protein lysate was
loaded in each lane. D) Relative abundance of C/EBPa showing decreased protein levels in response to LPS (1 μg/ml), but no effect in response
to oligomer-enriched Ab (10 μM) and/or IL-1b (10 ng/ml). E) Relative abundance of C/EBPδ showing increased protein levels in response to IL-1b
or LPS, and no change on response to IL-1b when oligomer-enriched Ab is present. The data represent mean ± SEM for two cultures derived
from three independent experiments. *p < 0.05, **p < 0.01, significantly different as indicated.
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C/EBPa p30 levels were ~31-33% lower compared with
age-matched non-transgenic littermates (Figure 3A,B).
Unfortunately the effect on p42 could not be deter-
mined due to co-migration of strong nonspecific bands
on the western blots. In contrast to a previous report of
findings in human AD patient tissue [20], the levels of
C/EBPδ were decreased ~62% in forebrain of aged tg-
ArcSwe mice compared with age-matched non-trans-
genic mice (Figure 4A). Total Ab levels in forebrain
from these aged tg-ArcSwe mice were 227 ± 48 ng Ab/
mg tissue (mean ± SEM, N = 6) and were below the
detection limit (i.e., <20 pg Ab/mg tissue) in non-trans-
genic mice. Our findings are consistent with the results
from IL-1b-activated astro-microglial cultures treated
with fibrilar Ab (Figure 2A,C). Analysis of the relatively
Ab plaque-free hindbrain showed a down-regulation of
C/EBPa p30 levels similar to that found in forebrain
(Figure 3B) indicating that this is not a local Ab plaque-
dependent phenomenon. In contrast, no difference in C/
EBPδ levels was observed in hindbrain when transgenic
mice and non-transgenic age-matched littermates were
compared (Figure 4B). To ensure that the changes in
levels of C/EBPs were due to age-dependent accumula-
tion of Ab and formation of Ab fibrils, and not some
unrelated effect of the transgene, brain tissue from
young tg-ArcSwe mice with low Ab load were analyzed
and compared with age-matched non-transgenic mice.
These experiments showed that there are no significant
differences between tg-ArcSwe mice and non-transgenic
mice with respect to C/EBPa p30 (Figure 3C,D) and C/
EBPδ levels (Figure 4C,D). However, direct comparison
of non-transgenic and tg-ArcSwe mice of different ages
indicated that C/EBPδ levels are down-regulated both in
response to age and Ab plaque burden (Figure 5A,B).
The C/EBPδ levels in forebrain were significantly
decreased in aged non-transgenic mice by ~51% and
further decreased in aged tg-ArcSwe mice by ~92%
compared to young animals. In contrast, the LAP iso-
form (~35 kDa) of C/EBPb was significantly up-regu-
l a t e d( ~ 2 7 %h i g h e r )i nt h ef o r e b r a i no fa g e dt g - A r c S w e
mice as compared to age-matched non-transgenic con-
trol (Figure 6A,B). C/EBPb LAP levels were below or
close to detection limit in the hindbrain of aged mice
and in both forebrain and hindbrain of young animals
and could therefore not be quantified.
IL-1b-increased binding activity of C/EBPδ is blocked by
fibril-enriched Ab preparations
To further investigate the effects of fibrillar forms of
Ab, EMSA was performed to analyze C/EBPδ binding
activity. Primary astro-microglial cells were treated for
Figure 2 Fibril-enriched Ab inhibits IL-1b-induced C/EBPδ
expression in rat primary astro-microglial cultures.A )
Representative western blot of C/EBPa (p42 and p30) and C/EBPδ in
primary astro-microglial cultures from newborn rat. Cells were
exposed to an Ab preparation highly enriched in fibrils for 3 h. 20
μg of protein lysate was loaded in each lane. B) Relative abundance
of C/EBPa showing significantly decreased protein levels in
response to LPS (1 μg/ml), but no significant effect in response to
fibril-enriched Ab (10 μM) or IL-1b (10 ng/ml). C) Relative
abundance of C/EBPδ showing increased levels in response to IL-1b
or LPS, and decreased C/EBPδ levels after exposure to IL-1b
together with Ab compared to treatment with IL-1b alone. The data
represent mean ± SEM for two cultures derived from three
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001,
significantly different from control or otherwise indicated.
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prior to harvesting. The results show that C/EBPδ
binding to double-stranded oligonucleotides containing
aC / E B Pb i n d i n gs i t ei sd o w n - r e g u l a t e db y~ 8 9 %i n
cultures concomitantly treated with IL-1b and fibril-
enriched Ab preparations compared to cells treated
with IL-1b alone (Figure 7A,B). The down-regulation
in DNA binding activity reflects the down-regulation
in protein level.
C/EBPδ binding to a B site induced by IL-1b is inhibited
by Ab
In order to test the hypothesis that C/EBPδ can shift its
preferable DNA binding site and binding partners, and
to analyze the effects of Ab,C / E B P δ binding to a B
response element was investigated. Nuclear extracts
from primary astro-microglial cultures treated for 3 h
with IL-1b together with Ab were analyzed in streptavi-
din-agarose pull-down experiments. Cells treated with
Figure 3 Decreased levels of C/EBPa also in brain areas with low Ab plaque burden from aged tg-ArcSwe mice. Relative abundance and
representative western blot of C/EBPa (p30) in forebrain (A) and pathology-spared hindbrain (B) from 15.5-17 month-old tg-ArcSwe mice (tg)
and non-transgenic mice (c). The results show a decrease in protein levels in both brain areas indicating that the observed down-regulation
does not directly relate to Ab plaque burden. The data represent mean ± SEM for six transgenic and six control mice. Young transgenic mice
did not show significantly altered expression in forebrain (C) or hindbrain (D). The data represent mean ± SEM for three transgenic and five
control mice. 40 μg of protein lysate was loaded in each lane and b-actin was used as a loading control. *p < 0.05, significantly different from
control. A.U., arbitrary units.
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pared to untreated control cells. In the presence of
fibril-enriched Ab,I L - 1 b-induced binding of C/EBPδ to
the B site was completely blocked (Figure 8A,B). We
also analyzed the effect of oligomer-enriched prepara-
tions of Ab. Surprisingly, the oligomeric conformation
of Ab decreased C/EBPδ binding to the Bs i t et ot h e
same extent as the fibrillar form in IL-1b activated cells
(Figure 8A,B).
Discussion
In this study we observed that IL-1b-induced expression
of C/EBPδ was inhibited in rat primary astro-microglial
cultures after exposure to Ab. However, this effect is
dependent on the presence of fibrillar forms of Ab and
no effect on protein levels was observed after exposure
to an oligomer-enriched Ab preparation. In general, C/
EBPδ is up-regulated in response to inflammatory sti-
muli. Our results instead indicate an Ab-dependent
Figure 4 Decreased levels of C/EBPδ in brain areas with high Ab plaque burden from aged tg-ArcSwe mice. Relative abundance and
representative western blot of C/EBPδ from forebrain (A) of aged tg-ArcSwe mice (tg) and non-transgenic mice (c) showing a decrease in
protein levels in amyloid-rich areas whereas the relatively Ab plaque-free hindbrain (B) does not show altered expression. The data represent
mean ± SEM for six transgenic and six control mice. Young transgenic mice did not show alterations in C/EBPδ expression compared to non-
transgenic littermates in forebrain (C) or hindbrain (D). The data represent mean ± SEM for three transgenic mice and five control mice. 40 μgo f
protein lysate was loaded in each lane and b-actin was used as a loading control. *p < 0.05, significantly different from control. A.U., arbitrary
units.
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Page 8 of 13decrease in C/EBPδ levels. This decrease of C/EBPδ was
further confirmed using an AD transgenic mouse
model, tg-ArcSwe mice, characterized by high levels of
fibrillar Ab deposits [25]. When analyzing brain areas of
aged mice carrying a high Ab load, C/EBPδ was signifi-
cantly down-regulated compared to the same brain
areas from aged non-transgenic littermates. This effect
on C/EBPδ levels is not the expected result since up-
regulation of inflammatory markers has been detected
in other AD transgenic mice models (cf., [34]). An Ab-
induced inflammatory response in tg-ArcSwe mice is,
however, supported by down-regulated C/EBPa levels
and up-regulated C/EBPb levels in forebrain from aged
tg-ArcSwe mice.
Differential effects of oligomeric and fibrillar forms of
Ab on glial cells have been reported earlier: Rat astro-
microglial cultures show significantly higher levels of
inflammatory markers, such as tumor necrosis factor
(TNF)-a, when exposed to oligomeric compared to
fibrillar Ab [35]. In microglial cells TNF-a induction is
typical for a classic cytotoxic phenotype, whereas an
alternative activation state is not correlated with
expression of inflammatory cytokines and is instead
characterized by increased Ab phagocytic capabilities. A
recent study in a PS1xAPP transgenic AD model showed
that hippocampal microglial cells switch from the alter-
native activation state to the classical cytotoxic pheno-
type during aging [36]. Interestingly, only microglia not
located in the vicinity of Ab plaques express this classi-
cal cytotoxic phenotype in 18-month-old transgenic
mice. Microglial cells surrounding plaques are instead
TNF-a negative. The same authors also showed that
both oligomeric Ab and soluble extract from 18-month-
old transgenic mouse hippocampus produces potent
TNF-a induction in astro-microglial cultures from non-
transgenic mice [36]. One possibility is that increased
expression of C/EBPδ is a marker for classical cytotoxic
glial cells and that the fibrillar form of Ab actually
blocks induction of this phenotype. This could also
explain the decreased levels of C/EBPδ that we observed
in brain areas with high Ab load in aged tg-ArcSwe
Figure 5 C/EBPδ levels are decreased with ageing and Ab
plaque formation. Relative abundance (A) and representative
western blot (B) of C/EBPδ from forebrain of young and aged tg-
ArcSwe mice (tg) and non-transgenic littermates (c). When
comparing C/EBPδ levels between young and aged mice, the results
indicate an overall C/EBPδ decrease not only in response to Ab but
also to age. The data represent mean ± SEM for five transgenic
mice and six control mice. 40 μg of protein lysate was loaded in
each lane and b-actin was used as a loading control. ***p < 0.001,
significantly different as indicated. A.U., arbitrary units.
Figure 6 Increased levels of C/EBPb in brain areas with high
Ab plaque burdens from aged tg-ArcSwe mice. A) Relative
abundance of C/EBPb showing increased protein levels in forebrain
of aged tg-ArcSwe mice (tg) compared to non-transgenic mice (c).
B) Representative western blot showing two isoforms of C/EBPb
(LAP and LIP). Only the C/EBPb LAP isoform was quantified. The
data represent mean ± SEM for six transgenic and six control mice.
40 μg of protein lysate was loaded in each lane and b-actin was
used as a loading control. *p < 0.05, significantly different from
control; crm, cross-reactive material (cf., [53,54]). C/EBPb protein
levels in hindbrain from aged mice and from both forebrain and
hindbrain from young mice were below or close to detection limit.
A.U., arbitrary units.
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Page 9 of 13mice, since the Arctic mutation not only increases the
rate of Ab protofibril formation but also fibril formation
and senile plaque deposition [26,37].
As indicated above, increased levels of C/EBPb and δ
are expected when an inflammatory response is induced.
It is believed that during inflammation the rapidly and
transiently activated NF-B pathway is crucial for a pri-
mary wave of gene induction and that a second and
more long-term wave of gene transcription is mediated
by other transcription factors including the C/EBP
family (cf., [12,38,39]). Members of the C/EBP family
can form heterodimers with NF-B subunits [9,11]. Pre-
vious studies have indicated a reciprocal cross-coupling
between NF-B and C/EBPs: NF-B and C/EBPs seem
to synergistically activate promoters with C/EBP sites,
and inhibit promoters with B motifs [10,38,40]. In this
s t u d yw es h o wt h a t ,i na s t r o - m i c r o g l i a lc e l l s ,I L - 1 b
induces binding of C/EBPδ-containing complexes to a
B site. It could be speculated that this is a part of a
negative feed-back mechanism regulating the effect of
NF-B activation. If this is true, the inhibition of C/
EBPδ binding to the B motif that we observe after
exposure to Ab could result in prolonged effects of NF-
B acting at this site.
When the astro-microglial cells were exposed to fibril-
enriched Ab preparations the IL-1b-induced binding of
C/EBPδ to both the C/EBP and the Bm o t i f sw e r e
more or less abolished. This could be expected since the
IL-1b-induced increase of C/EBPδ protein levels was
strongly reduced by Ab fibrils. However, the effect of
oligomer-enriched Ab preparations on C/EBPδ binding
activity was not expected. Although no effect could be
observed on protein levels, IL-1b-induced binding of C/
Figure 7 C/EBPδ binding activity induced by IL-1b is blocked
by Ab fibrils. A) Representative EMSA showing inhibition of IL-1b-
(10 ng/ml) induced C/EBPδ binding activity in primary astro-
microglial cultures exposed to fibril-enriched Ab (10 μM) for 3 h. B)
Relative abundance of C/EBPδ binding activity showing that fibril-
enriched Ab inhibits IL-1b-induced C/EBPδ binding, but has no
effect on its own. The data represent mean ± SEM for two cultures
derived from three to six independent experiments. *p < 0.05, **p <
0.01, significantly different from control or otherwise indicated.
Figure 8 IL-1b-induced C/EBPδ binding to a B site is inhibited
by Ab. A) Representative western blot of C/EBPδ after streptavidin-
agarose pull-down using biotinylated B oligonucleotides. Primary
astro-microglial cells were exposed to oligomer- or fibril-enriched
preparations of Ab (10 μM, oAb or fAb) in combination with IL-1b
(10 ng/ml) for 3 h. B oligonucleotides without biotin were used as
a control for unspecific binding. B) Relative levels of C/EBPδ binding
to the B site showing that IL-1b induces a significant increase that
is inhibited after Ab exposure. The data represent mean ± SEM for
three independent experiments. *p < 0.05, **p < 0.01, significantly
different from control or otherwise indicated.
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Page 10 of 13EBPδ to the B site was decreased to the same degree as
after treatment with Ab fibrils. In addition, we showed
in a previous study that oligomer-enriched Ab prepara-
tions also decrease the binding of C/EBPδ to the C/EBP
site [21]. Taken together these results indicate that oli-
gomer-enriched Ab affects the functional properties of
C/EBPδ rather than expression levels.
The activity of C/EBPs has been shown to be depen-
dent upon phosphorylation. Phosphorylation can occur
in a negative regulatory domain of C/EBPs and is
believed to relieve the inhibitory effect on their DNA
binding and transactivation domains [41,42]. C/EBPb
has a conserved MAPK consensus phosphorylation
motif [43]. Phosphorylation induced by the Ras pathway
upon inflammatory stimuli will lead to a switch from a
repressed to an active conformation [43-45]. In murine
embryonic fibroblasts, LPS-induced expression of both
C/EBPb and δ is dependent on NF-Bp65 and IB
kinase (IKK) 2 [46]. In cells lacking the IKK-related
kinase IKKi, LPS will still activate NF-Ba n di n d u c eC /
EBPb and δ expression, but C/EBPδ-specific DNA bind-
ing is absent [46].
IL-1b, as well as other inflammatory stimuli, has been
shown to activate the Ras pathway [47]. The Ras path-
way in turn can result in both extracellular signal-regu-
lated kinase (ERK) 1/2 and IKKi activation [48]. A
recent study showed that LPS-induced upregulation of
C/EBPδ in a microglial cell line could be prevented by
an ERK inhibitor [31]. Both LPS-induced C/EBPδ pro-
tein expression and DNA binding to a C/EBP motif
have been reported to be blocked by a combination of
MAP kinase inhibitors (ERK/JNK/p38 inhibitors) [49].
Interestingly, an age-dependent and significant reduction
of the active form of ERK1 (phosphoERK1; pERK1) has
been observed in cerebral cortex from the AD-trans-
genic mouse model tg2576/PS1
P264L [50]. In addition, in
the tg2576 mice model, which shows a slower build-up
of amyloid burden, a slight, but significant, increase of
pERK2 is observed in CA1 of hippocampus at 13
months of age. This is followed by a significant reduc-
tion at 20 months of age [51]. Thus, it is possible that
our results showing decreased levels of C/EBPδ both in
astro-microglial cultures exposed to Ab fibrils and in
aged tg-ArcSwe mice could be explained by reduced
MAP kinase activity.
Our results showing decreased levels of C/EBPδ both
in astro-microglial cultures exposed to Ab fibrils and in
aged tg-ArcSwe mice seems contradictory to a previous
study from Rogers’ laboratory showing up-regulated C/
EBPδ in AD brains [20]. However, as discussed above,
data from transgenic mouse models indicate that the
effect on C/EBPδ may correlate with a later phase when
build-up of fibrillar Ab deposits reaches a certain level
that will lead to reduced expression of C/EBPδ.I tm a y
be assumed that the ratio Ab fibrils:oligomers may be
lower in brain tissue from patients with the sporadic
form of AD as compared to aged tg-ArcSwe transgenic
mice. However, it cannot be ruled out that DNA bind-
ing and transcriptional activity is reduced also in AD
brain since we propose that oligomer-enriched Ab dis-
turbs the functional properties of C/EBPδ rather than
expression levels.
The C/EBP family members exert pleiotropic effects in
tissues in which they are expressed and are also
expressed in a number of different cell types. C/EBPa,
b,a n dδ are all expressed in primary astro-microglial
cultures. At least in human AD brains, C/EBPδ immu-
noreactivity seems to localize primarily to astrocytes
[20]. However, in brain tissue from mice neuronal loca-
lization of C/EBPs has also been reported [20,52] and
this may also explain the high levels of C/EBPδ in
young mice. At this point we have not identified the cell
types which are responsible for the effects on tissue
levels of C/EBPa, b, and δ in tg-ArcSwe mouse brain. It
is also possible that the differential effects on the differ-
ent isoforms (i.e., decreased levels of C/EBPa in both
affected and non-affected brain areas, increased levels of
C/EBPb in affected areas and decreased levels of C/
EBPδ only in affected areas) mirror the effects of Ab
deposits on different cell types.
Conclusions
Our results indicate that different aggregation states
of Ab affect the transcription factor C/EBPδ differ-
ently during inflammatory conditions. Ab oligomers,
o nt h eo n eh a n d ,s e e mt oh a v ea ne f f e c to nC / E B P δ
function, as shown by reduced DNA binding activity
induced by IL-1b, rather than affecting C/EBPδ pro-
tein levels. Ab f i b r i l s ,o nt h eo t h e rh a n d ,r e d u c eb o t h
protein expression levels and binding activity to C/
EBP and Bs i t e s .In vivo studies using aged plaque-
depositing tg-ArcSwe mice further confirm down-reg-
ulation of C/EBPδ caused by the presence of Ab
fibrils. We propose that AD pathology causes an
imbalance between NF-Ba n dC / E B Pt r a n s c r i p t i o n
factors that may result in abnormal responses to
inflammatory stimuli. However, the functional conse-
quences of a disturbed C/EBPδ signaling in AD
remain to be determined.
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